trial

Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia

NCTId NCT04456777
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Unknown
Enrollment 120 (estimated)
Sponsored by Alen Greš
Primary completion 2022-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Unknown
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2020-07-01
Primary completion
2022-07-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Vortioxetine

Sponsors

Alen GrešLead Sponsor

Sites

1 total
Zagreb, Croatia

Facts & assertions

4 sourced
Enrollment
120
Phase
EARLY_PHASE1
Primary Completion Date
2022-07-01
Status
UNKNOWN
relationships
The graph out of here
drug
Vortioxetine
drug
lead_sponsor
Alen Greš
company
indication
Cognitive Deficit
indication
Cognition Disorders
indication